Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $62.89 down -0.02% from its previous closing price of $62.9. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 2.14 million shares were traded. HALO stock price reached its highest trading level at $63.66 during the session, while it also had its lowest trading level at $62.49.
Ratios:
For a deeper understanding of Halozyme Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.42 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.60. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 4.54 whereas as Long-Term Debt/Eq ratio is at 4.54.
Morgan Stanley Downgraded its Overweight to Equal-Weight on May 14, 2025, while the target price for the stock was maintained at $62.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 10 ’25 when Torley Helen sold 20,000 shares for $57.43 per share. The transaction valued at 1,148,618 led to the insider holds 733,719 shares of the business.
Torley Helen sold 20,000 shares of HALO for $1,128,655 on Jul 09 ’25. The PRESIDENT AND CEO now owns 733,719 shares after completing the transaction at $56.43 per share. On Jul 08 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $55.51 each. As a result, the insider received 1,110,245 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 7355991552 and an Enterprise Value of 8345884672. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.37, and their Forward P/E ratio for the next fiscal year is 8.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.24 while its Price-to-Book (P/B) ratio in mrq is 22.23. Its current Enterprise Value per Revenue stands at 7.081 whereas that against EBITDA is 11.002.
Stock Price History:
The Beta on a monthly basis for HALO is 1.18, which has changed by 0.1232363 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $70.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 11.88%, while the 200-Day Moving Average is calculated to be 12.67%.
Shares Statistics:
For the past three months, HALO has traded an average of 2.47M shares per day and 2288910 over the past ten days. A total of 117.62M shares are outstanding, with a floating share count of 115.67M. Insiders hold about 1.10% of the company’s shares, while institutions hold 103.89% stake in the company. Shares short for HALO as of 1752537600 were 9602474 with a Short Ratio of 3.88, compared to 1749772800 on 11065499. Therefore, it implies a Short% of Shares Outstanding of 9602474 and a Short% of Float of 10.67.
Earnings Estimates
The current market rating for Halozyme Therapeutics Inc (HALO) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.97, with high estimates of $2.47 and low estimates of $1.79.
Analysts are recommending an EPS of between $6.34 and $6.06 for the fiscal current year, implying an average EPS of $6.19. EPS for the following year is $7.58, with 6.0 analysts recommending between $8.49 and $5.66.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $339.74M this quarter.It ranges from a high estimate of $350M to a low estimate of $331.4M. As of the current estimate, Halozyme Therapeutics Inc’s year-ago sales were $290.08MFor the next quarter, 7 analysts are estimating revenue of $392.21M. There is a high estimate of $405.7M for the next quarter, whereas the lowest estimate is $378.4M.
A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.52B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.34B. In the same quarter a year ago, actual revenue was $1.02BBased on 8 analysts’ estimates, the company’s revenue will be $1.6B in the next fiscal year. The high estimate is $1.69B and the low estimate is $1.43B.
